查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1806204

再生医学市场（按产品类型、来源、应用领域和最终用户）—2025-2030 年全球预测

Regenerative Medicine Market by Product Type, Source, Application Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

再生医学市场预计到 2024 年将达到 283.5 亿美元，2025 年将达到 349.9 亿美元，到 2030 年将达到 1,024 亿美元，复合年增长率为 23.86%。

主要市场统计数据
基准年2024年 283.5亿美元
预计2025年 349.9亿美元
预测年份 2030 1024亿美元
复合年增长率（%） 23.86%

探索再生医学作为现代医疗创新和治疗发展的变革前沿的不断发展的前景

再生医学正处于模式转移的风口浪尖，这将重新定义治疗慢性和退化性疾病的可能性。在细胞生物学、生物材料科学和基因编辑技术的推动下，该领域正从理论可能性走向具体的临床实践。从干细胞疗法的开创性努力到基于细胞的精细方法，研究人员和临床医生都见证了前所未有的治疗潜力。随着全球医疗生态系统努力应对心血管疾病、神经系统疾病和复杂伤口日益增多的趋势，再生策略为传统药物介入提供了极具吸引力的替代方案。因此，在学术界、产业界和监管机构的协力网路的支持下，研发投入正在激增。

确定推动再生医学模式转移的关键曲折点，塑造充满活力的未来治疗创新生态系统

再生医学领域正经历一系列曲折点，重塑其策略方向。精准基因编辑领域的最新突破促进了治疗有效载荷的更高效递送，弥合了概念研究与可扩展临床应用之间的差距。同时，人工智慧和机器学习工具的整合正在透过加速标靶发现和优化生产流程来缩短开发时间。与这些技术加速器相辅相成的是主要市场的先进法律规范，这些框架正在引入快速核准途径和自适应许可模式，以更快地满足未满足的医疗需求。

评估2025年美国关税变化对国际再生医学供应网络和合作研究联盟的影响

2025年，美国实施了一系列关税调整，对全球再生医学供应网络产生了显着的连锁反应。儘管其初衷是为了保护国内产能，但对生物原料、病毒载体和专用支架组件的进口关税上调，却增加了许多国际合作伙伴的生产成本。因此，製造商和研究机构不得不重新思考筹资策略，探索近岸外包机会和其他区域中心，以缓解不断上升的成本压力。

揭示深层市场细分视角，揭示再生医学产品、供应商、应用和最终用户的策略路径

细緻入微地了解市场区隔对于制定策略投资和确定研究路径的优先顺序至关重要。根据产品类型，该领域涵盖多种模式，从细胞疗法到细胞外和细胞培养方法、基因疗法解决方案和组织工程平台。在细胞疗法中，区分无干细胞治疗方法，例如树突状细胞、自然杀手细胞和 T 细胞等免疫细胞产品，以及利用多功能细胞或成体前驱细胞群的基于干细胞的治疗方法。基因编辑技术、基因递送载体以及基于 RNA 和 DNA 的系统带来了额外的复杂性，载体分类扩展到非病毒和病毒平台。组织工程进一步细分为生医材料、生长因子和细胞激素配方以及支架构建体，天然生物材料和合成生医材料的选择决定了性能和成本生医材料的差异。

分析美洲、中东和非洲以及亚太地区再生医学生态系中塑造机会的区域动态

区域差异在塑造再生医学领域的投资决策、监管趋势和商业化策略方面发挥关键作用。在美洲，强劲的私人和公共资金筹措正在加速临床应用，大幅扩大先进製造地，并简化新治疗方法的核准流程。该地区领先的研究机构和行业相关人员之间的跨境合作正在建立卓越中心，并促进最先进治疗的快速迭代。

与业界领先的先驱者会面，他们透过策略合作伙伴关係引领再生医学的商业道路

领先的公司正在透过多元化策略发展其产品组合，以平衡内部研发与外部合作。一些先锋生物製药公司正在建立专门的细胞和基因治疗部门，以汇集专业知识并加速产品线开发。这些团队利用内部能力以及与学术中心和专业合约开发公司的策略伙伴关係，获得灵活性和规模。合资企业也正在成为共同投资製造基础设施的首选方式，以确保在整个开发过程中利益一致、风险共用。

提供有针对性的建议，使领导者能够加速创新，推动永续成长，并克服再生医学领域的关键挑战

为了因应复杂的再生医学环境，产业领导者应采取涵盖策略、营运和监管等多方面措施。首先，与学术机构和专业合约组织建立强而有力的伙伴关係关係，可以加速研发管线的进展，同时降低资本支出风险。协调奖励并共同投资模组化製造平台，可以帮助相关人员在生产需求不断增长的情况下保持敏捷。

我们严谨的调查方法，结合原始资料和二次资料分析，提供全面的再生医学见解

本报告中提出的见解是基于严格的混合方法框架，旨在确保研究的深度和有效性。主要研究包括对一系列相关人员的深入访谈，涵盖从科学创始人和製程工程师到监管专家和商业策略家的方方面面。这些对话旨在揭示关于技术采用、监管趋势和临床开发挑战的微妙观点。同时，二次资料分析借鉴了同行评审文献、政府政策文件和公开的临床试验库，以检验新兴趋势和基准。

全球再生医学动态和市场影响因素综合研究的关键要点和策略重点摘要

再生医学领域正处于曲折点，其特征包括技术突破、监管格局的演变以及全球供应网络的策略调整。在支持性政策框架和不断提升的生产能力的推动下，先进的细胞和基因疗法正从实验阶段走向近期的商业化阶段。主要市场的关税调整带来了成本压力和供应链复杂性，同时也催化了本地生产和建立韧性伙伴关係的创新策略。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 扩大慢性创伤治疗的再生疗法
  • 基因编辑技术的进步加速创新
  • 产学合作促进再生产品开发
  • 透过人工智慧整合优化再生医学研究
  • 对抗老龄化相关疾病的再生解决方案需求不断增长
  • 新型生物材料的出现增强了支架在再生的有效性
  • 3D生物列印技术在组织工程的应用日益广泛
  • 干细胞疗法的进步推动个人化再生治疗
  • 监管演变改善再生医学核准途径
  • 支持再生医学Start-Ups企业和临床试验的投资激增

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章再生医学市场（依产品类型）

  • 细胞疗法
    • 非干细胞疗法
      • 免疫细胞
      • 树突状细胞
      • 自然杀手（NK）细胞
      • T细胞
      • 非免疫细胞
    • 干细胞疗法
  • 细胞外和无细胞疗法
  • 基因治疗
    • 基因编辑技术
    • 基因转移载体
      • 非病毒载体
      • 病毒载体
    • 基于RNA和DNA的治疗方法
  • 组织工程
    • 生物材料
      • 天然生医材料
      • 合成生医材料
    • 生长因子和细胞激素
    • 鹰架

第九章 再生医学市场（依来源）

  • 同种异体
  • 自体移植
  • 合成
  • 异质

第 10 章 再生医学市场（按应用）

  • 心血管系统
    • 血管生成和血管重建
    • 先天性心臟疾病修復
    • 心臟瓣膜置换术
    • 心肌梗塞的治疗
  • 皮肤科
    • 美容手术
    • 烧烫伤治疗
    • 慢性创伤治疗
  • 糖尿病
    • β细胞移植
    • 胰岛细胞再生
  • 神经病学
    • 阿兹海默症治疗
    • 多发性硬化症的治疗
    • 帕金森氏症的治疗
    • 脊髓损伤修復
    • 中风復健
  • 肿瘤学
    • 癌症免疫治疗
    • 肿瘤消融
  • 眼科
    • 角膜修復
    • 视网膜再生
  • 整形外科和肌肉骨骼
    • 骨再生
    • 软骨修復
    • 肌腱修復

第 11 章 再生医学市场（依最终使用者）

  • 学术研究机构
  • 合约研究组织
  • 医院和诊所
  • 製药和生物技术公司

第 12 章：美洲再生医学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 13 章：欧洲、中东和非洲的再生医学市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第 14 章：亚太再生医学市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • 4D Molecular Therapeutics, Inc.
    • AbbVie Inc.
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics PLC
    • Adverum Biotechnologies, Inc.
    • AGC Biologics
    • Astellas Pharma Inc.
    • Bayer AG
    • CMIC Co., Ltd.
    • CRISPR Therapeutics AG
    • F. Hoffmann-La Roche Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Holdings Corporation
    • Gilead Sciences, Inc.
    • HEALIOS KK
    • Integra LifeSciences Holdings Corporation
    • JCR Pharmaceuticals Co., Ltd.
    • Johnson & Johnson
    • Merck KGaA
    • Mesoblast Limited
    • Novartis AG
    • Orchard Therapeutics PLC
    • Organogenesis Holdings Inc.
    • Pfizer Inc.
    • Pluri Biotech Ltd.
    • Poseida Therapeutics, Inc.
    • REPROCELL Inc.
    • SanBio Company Limited
    • Stryker Corporation
    • Sumitomo Pharma Co., Ltd.
    • Sysmex Corporation
    • Takeda Pharmaceutical Company Limited
    • Tenaya Therapeutics, Inc.
    • Vericel Corporation
    • Voyager Therapeutics Inc.
    • Zimmer Biomet Holdings, Inc.

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market was valued at USD 28.35 billion in 2024 and is projected to grow to USD 34.99 billion in 2025, with a CAGR of 23.86%, reaching USD 102.40 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 28.35 billion
Estimated Year [2025] USD 34.99 billion
Forecast Year [2030] USD 102.40 billion
CAGR (%) 23.86%

Exploring the Evolutionary Landscape of Regenerative Medicine as a Transformative Frontier in Modern Healthcare Innovation and Therapeutic Development

Regenerative medicine stands at the cusp of a paradigm shift, redefining what is possible in the treatment of chronic and degenerative diseases. Fueled by advances in cell biology, biomaterials science, and gene editing technologies, this discipline is moving beyond theoretical promise into tangible clinical realities. From pioneering trials in stem cell therapies to the refinement of acellular approaches, researchers and clinicians alike are witnessing unprecedented therapeutic potential. As the global healthcare ecosystem grapples with rising incidences of cardiovascular disorders, neurological conditions, and complex wounds, regenerative strategies offer a compelling alternative to traditional pharmacological interventions. Consequently, investment in research and development has surged, supported by collaborative networks spanning academia, industry, and regulatory bodies.

In response to these trends, this executive summary distills the critical developments shaping the regenerative medicine landscape. It highlights key technological breakthroughs, examines the evolving regulatory environment, and explores how shifting reimbursement paradigms are influencing stakeholder decision-making. Moreover, this report delves into supply chain dynamics and policy influences that will dictate future trajectories. By synthesizing qualitative insights from expert interviews with rigorous secondary analysis, the summary offers a comprehensive foundation for strategic planning. Ultimately, this introduction sets the stage for an in-depth examination of transformative shifts, tariff implications, segmentation patterns, regional dynamics, and actionable recommendations essential for leaders seeking to capitalize on the regenerative medicine revolution.

Identifying Critical Inflection Points Driving the Paradigm Shift in Regenerative Therapies and Shaping a Dynamic Future Ecosystem of Treatment Innovation

The regenerative medicine sector is experiencing a series of inflection points that are collectively reshaping its strategic direction. Recent breakthroughs in precision gene editing have facilitated more efficient delivery of therapeutic payloads, bridging the gap between conceptual research and scalable clinical application. At the same time, integration of artificial intelligence and machine learning tools is accelerating target discovery and optimizing manufacturing workflows, thereby reducing development timelines. These technological accelerators are complemented by progressive regulatory frameworks in key markets, which are progressively offering accelerated approval pathways and adaptive licensing models to address unmet medical needs more rapidly.

Simultaneously, growing alignment between biopharmaceutical sponsors and specialized contract development and manufacturing organizations is fostering greater agility and cost-effectiveness within supply chains. This shift reflects a broader ecosystem trend toward modular, flexible manufacturing that can accommodate personalized therapies and small-batch production. In parallel, rising engagement from venture capital and nontraditional investors signals heightened confidence in the commercial viability of regenerative products. As public-private partnerships evolve and philanthropic funding supports early-stage innovation, the sector is transitioning from siloed research efforts into a cohesive network of collaborative ventures. Consequently, stakeholders must navigate an increasingly dynamic environment characterized by cross-disciplinary alliances, regulatory flexibility, and next-generation manufacturing strategies.

Assessing the Impact of United States Tariff Changes in 2025 on International Regenerative Medicine Supply Networks and Collaborative Research Alliances

In 2025, the United States implemented a series of tariff adjustments that have generated substantial ripple effects throughout the global regenerative medicine supply network. While the intention was to protect domestic manufacturing capabilities, increased import duties on raw biomaterials, viral vectors, and specialized scaffolding components have elevated production costs for many international partners. Consequently, manufacturers and research institutions have had to recalibrate sourcing strategies, exploring nearshoring opportunities and alternative regional hubs to mitigate escalating expense pressures.

Moreover, these tariff changes have spurred a strategic realignment of collaborative research alliances. Firms are seeking to establish integrated supply chain partnerships within tariff-friendly jurisdictions, thereby preserving cost efficiencies while maintaining access to critical inputs. Academic and contract organizations have intensified negotiations to secure long-term procurement contracts, often involving co-investment in localized production facilities. Although these measures have introduced temporary delays in certain clinical trial timelines, they have also catalyzed innovative manufacturing approaches, such as single-use bioreactors and modular cleanroom systems, which reduce dependence on cross-border shipments.

Looking ahead, stakeholders must remain vigilant to policy shifts that could further influence trade dynamics. Engaging proactively with regulatory and legislative bodies will be crucial to shaping more balanced tariff frameworks and developing resilient supply networks. In doing so, industry participants can safeguard research continuity, accelerate product development, and foster sustainable growth despite evolving trade policies.

Unveiling Deep Market Segmentation Perspectives to Illuminate Strategic Pathways in Product, Source, Application, and End User Dimensions of Regenerative Medicine

A nuanced understanding of market segmentation is essential for framing strategic investments and prioritizing research pathways. Based on product type, the sector encompasses a diverse array of modalities ranging from cell therapy to extracelluar and acellular approaches, gene therapy solutions, and tissue engineering platforms. Within cell therapy, distinctions emerge between non-stem cell-based modalities-such as immune cell products including dendritic cells, natural killer cells, and T cells-and stem cell-based interventions that leverage pluripotent and adult progenitor populations. Gene editing technologies, gene transfer vectors, and RNA- or DNA-based systems present additional layers of complexity, with vector classifications extending to non-viral and viral-based platforms. Tissue engineering further subdivides into biomaterials, growth factor and cytokine formulations, and scaffold constructs, wherein the choice between natural and synthetic biomaterials drives differential performance and cost profiles.

When considering source origin, therapeutic products are categorized as allogeneic, autologous, synthetic, or xenogeneic, each possessing distinct immunological and manufacturing considerations. Application areas span a broad clinical spectrum, including cardiovascular interventions for angiogenesis and valve repair, dermatological treatments for burn wounds and chronic lesions, and diabetes therapeutics focused on beta cell transplantation. Neurology targets encompass Alzheimer's disease, multiple sclerosis, Parkinson's therapeutics, spinal cord repair, and post-stroke recovery, while oncology strategies leverage immunotherapy and ablative modalities. Ophthalmological innovations address corneal and retinal regeneration, and orthopedic and musculoskeletal repairs concentrate on bone, cartilage, and tendon restoration. End users range from academic research centers and contract research organizations to hospitals, clinics, and pharmaceutical and biotechnology enterprises, each bringing unique procurement criteria and adoption timelines to the landscape.

Analyzing Regional Dynamics Shaping Opportunities in the Americas, Europe Middle East Africa, and Asia Pacific Across the Regenerative Medicine Ecosystem

Regional nuances play a pivotal role in shaping investment decisions, regulatory trajectories, and commercialization strategies across the regenerative medicine field. In the Americas, robust funding from private and public sources has accelerated clinical translation, with notable expansion of advanced manufacturing hubs and streamlined approval processes for novel therapies. Cross-border collaborations between leading research institutions and industry participants in this region have established centers of excellence, fostering rapid iteration of cutting-edge treatments.

Transitioning to Europe, the Middle East, and Africa, a mosaic of regulatory frameworks and reimbursement models influences market entry strategies. While some jurisdictions offer adaptive regulatory pathways and research incentives, others maintain more conservative approaches that require comprehensive safety and efficacy data. Consequently, strategic alliances and consortium-based research initiatives are common tools for managing heterogeneous policy landscapes. Emerging markets within this region are increasingly attractive for early-stage trials, owing to evolving infrastructure and competitive cost environments.

Across the Asia Pacific, ambitious government programs and supportive policy initiatives have catalyzed exponential growth in both academic research and commercial manufacturing capacity. Local manufacturers are investing heavily in scalable bioproduction facilities, while multinational companies are engaging in technology transfer agreements to localize supply chains. The convergence of favorable regulatory reforms, growing patient populations, and competitive operational costs has positioned this region as a critical hub for future regenerative medicine innovation.

Highlighting Leading Industry Pioneers Driving Competition through Strategic Alliances That Are Redefining Commercialization Pathways in Regenerative Medicine

Leading organizations are advancing portfolios through diverse strategies that balance internal R&D with external collaborations. Several pioneering biopharma firms have established dedicated cell and gene therapy divisions to consolidate expertise and accelerate pipeline development. These teams leverage in-house capabilities alongside strategic partnerships with academic centers and specialized contract developers to enhance flexibility and scale. Joint ventures are also emerging as a preferred vehicle for co-investing in manufacturing infrastructure, ensuring aligned incentives and shared risk across development timelines.

Furthermore, innovative biotech start-ups are differentiating themselves by targeting niche applications such as neuroregeneration and immuno-oncology, often supported by venture capital and philanthropic grants. These nimble players benefit from agile decision-making processes, allowing them to pivot rapidly based on emerging preclinical and clinical data. Meanwhile, established pharmaceutical companies are incorporating regenerative modalities into existing therapeutic platforms, integrating novel cell or gene therapies with established small molecule or biologic regimens to deliver combination treatments.

Across the ecosystem, intellectual property strategies are evolving to cover not only core therapeutic constructs but also manufacturing processes, delivery devices, and data analytics algorithms. This holistic approach safeguards competitive advantage while enabling cross-licensing arrangements that facilitate market entry. As the competitive landscape intensifies, effective portfolio management and alignment of scientific expertise with operational excellence will remain critical determinants of success.

Delivering Targeted Recommendations to Empower Leaders to Accelerate Innovation, Foster Sustainable Growth and Overcome Key Challenges in Regenerative Medicine

To navigate the complex regenerative medicine environment, industry leaders should adopt a multifaceted approach that spans strategic, operational, and regulatory dimensions. First, forging robust partnerships with academic institutions and specialized contract organizations can accelerate pipeline progression while mitigating capital expenditure risks. By aligning incentives and co-investing in modular manufacturing platforms, stakeholders can maintain agility even as production demands scale.

Second, investing in advanced analytics and digital technologies will be paramount to optimizing clinical trial design and real-time monitoring. Leveraging machine learning for patient stratification and predictive safety assessments can reduce development timelines and enhance trial success rates. Concurrently, establishing robust quality management systems and early engagement with regulatory authorities will streamline approval pathways and support adaptive trial models.

Third, diversifying geographic footprint through the establishment of regional centers of excellence can safeguard against policy volatility and supply chain disruptions. Engaging proactively in policy dialogues and public-private partnerships will help shape balanced regulatory frameworks while unlocking incentives for local production. Lastly, cultivating a holistic intellectual property strategy that encompasses core assets, manufacturing know-how, and data management algorithms will ensure differentiated market positioning. By executing these targeted recommendations, leaders can accelerate innovation, sustain competitive advantage, and deliver transformative therapies to patients worldwide.

Detailing a Rigorous Research Methodology Integrating Primary Interviews with Secondary Data Analysis to Deliver Comprehensive Regenerative Medicine Insights

The insights presented in this report are grounded in a rigorous mixed-methodology framework designed to ensure both depth and validity. Primary research included in-depth interviews with a cross-section of stakeholders, ranging from scientific founders and process engineers to regulatory experts and commercial strategists. These conversations were structured to uncover nuanced perspectives on technology adoption, regulatory trends, and clinical development challenges. In parallel, secondary data analysis leveraged peer-reviewed literature, government policy documents, and publicly disclosed clinical trial repositories to validate emerging trends and benchmarks.

To triangulate findings, an expert validation panel comprising thought leaders from academia, industry associations, and non-profit research organizations reviewed preliminary conclusions. This validation step was integral for refining thematic priorities and verifying the accuracy of market segmentation frameworks. Methodological rigor was further enhanced through consistency checks and cross-regional comparisons, ensuring that insights account for local policy nuances and supply chain dynamics. By integrating qualitative depth with quantitative context, this report delivers a comprehensive and actionable perspective on the global regenerative medicine landscape.

Summarizing Key Takeaways and Strategic Imperatives from the Comprehensive Examination of Regenerative Medicine Dynamics and Market Influencers Worldwide

The regenerative medicine sector is at an inflection point defined by technological breakthroughs, evolving regulatory landscapes, and strategic realignments within global supply networks. Advanced cell and gene therapies are transitioning from experimental stages to near-term commercialization, driven by supportive policy frameworks and expanding manufacturing capabilities. While tariff adjustments in key markets have introduced cost pressures and supply chain complexities, they have also catalyzed innovative strategies for localized production and resilient partnerships.

Segmentation analysis reveals the multiplicity of therapeutic modalities and end-user requirements, underscoring the importance of tailored approaches across product types, sources, application areas, and organizational buyers. Regional insights highlight the Americas, Europe Middle East Africa, and Asia Pacific as critical ecosystems, each offering unique advantages in terms of funding, regulatory agility, and infrastructure. Competitive dynamics continue to be shaped by strategic alliances, intellectual property portfolios, and investments in digital platforms for clinical and manufacturing optimization.

Looking forward, stakeholders must embrace collaborative innovation models, proactive policy engagement, and adaptive commercialization strategies to capitalize on the full potential of regenerative medicine. By synthesizing these key takeaways and imperatives, industry participants can better position themselves to deliver transformative therapies, drive sustainable growth, and ultimately improve patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of regenerative therapies targeting chronic wound healing
  • 5.2. Growth of gene editing techniques accelerating regenerative medicine innovation
  • 5.3. Collaborations between academia and industry fueling regenerative product development
  • 5.4. Integration of artificial intelligence to optimize regenerative medicine research
  • 5.5. Rising demand for regenerative solutions addressing age-related disorders
  • 5.6. Emergence of novel biomaterials enhancing scaffold effectiveness in regeneration
  • 5.7. Increasing adoption of 3D bioprinting technology in tissue engineering
  • 5.8. Advancements in stem cell therapies driving personalized regenerative treatments
  • 5.9. Regulatory evolution improving approval pathways for regenerative treatments
  • 5.10. Surge in investments supporting regenerative medicine startups and clinical trials

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Regenerative Medicine Market, by Product Type

  • 8.1. Introduction
  • 8.2. Cell Therapy
    • 8.2.1. Non-Stem Cell-Based Therapy
      • 8.2.1.1. Immune Cells
      • 8.2.1.1.1. Dendritic Cells
      • 8.2.1.1.2. Natural Killer (NK) Cells
      • 8.2.1.1.3. T Cells
      • 8.2.1.2. Non-immune Cells
    • 8.2.2. Stem Cell-Based Therapy
  • 8.3. Extracellular & Acellular Therapies
  • 8.4. Gene Therapy
    • 8.4.1. Gene Editing Technologies
    • 8.4.2. Gene Transfer Vectors
      • 8.4.2.1. Non-Viral Vectors
      • 8.4.2.2. Viral Vectors
    • 8.4.3. RNA & DNA-Based Therapies
  • 8.5. Tissue Engineering
    • 8.5.1. Biomaterials
      • 8.5.1.1. Natural Biomaterials
      • 8.5.1.2. Synthetic Biomaterials
    • 8.5.2. Growth Factors & Cytokines
    • 8.5.3. Scaffolds

9. Regenerative Medicine Market, by Source

  • 9.1. Introduction
  • 9.2. Allogeneic
  • 9.3. Autologous
  • 9.4. Synthetic
  • 9.5. Xenogeneic

10. Regenerative Medicine Market, by Application Areas

  • 10.1. Introduction
  • 10.2. Cardiovascular
    • 10.2.1. Angiogenesis & Vascular Regeneration
    • 10.2.2. Congenital Heart Defect Repair
    • 10.2.3. Heart Valve Replacement
    • 10.2.4. Myocardial Infarction Treatment
  • 10.3. Dermatology
    • 10.3.1. Aesthetic Procedures
    • 10.3.2. Burn Treatment
    • 10.3.3. Chronic Wound Healing
  • 10.4. Diabetes
    • 10.4.1. Beta Cell Transplantation
    • 10.4.2. Islet Cell Regeneration
  • 10.5. Neurology
    • 10.5.1. Alzheimer's Treatment
    • 10.5.2. Multiple Sclerosis Therapy
    • 10.5.3. Parkinson's Therapy
    • 10.5.4. Spinal Cord Injury Repair
    • 10.5.5. Stroke Recovery
  • 10.6. Oncology
    • 10.6.1. Cancer Immunotherapy
    • 10.6.2. Tumor Ablation
  • 10.7. Ophthalmology
    • 10.7.1. Corneal Repair
    • 10.7.2. Retinal Regeneration
  • 10.8. Orthopedic & Musculoskeletal
    • 10.8.1. Bone Regeneration
    • 10.8.2. Cartilage Repair
    • 10.8.3. Tendon Repair

11. Regenerative Medicine Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Contract Research Organizations
  • 11.4. Hospitals & Clinics
  • 11.5. Pharmaceutical & Biotechnology Companies

12. Americas Regenerative Medicine Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Regenerative Medicine Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Regenerative Medicine Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 4D Molecular Therapeutics, Inc.
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Abeona Therapeutics Inc.
    • 15.3.4. Adaptimmune Therapeutics PLC
    • 15.3.5. Adverum Biotechnologies, Inc.
    • 15.3.6. AGC Biologics
    • 15.3.7. Astellas Pharma Inc.
    • 15.3.8. Bayer AG
    • 15.3.9. CMIC Co., Ltd.
    • 15.3.10. CRISPR Therapeutics AG
    • 15.3.11. F. Hoffmann-La Roche Ltd.
    • 15.3.12. Fate Therapeutics, Inc.
    • 15.3.13. FUJIFILM Holdings Corporation
    • 15.3.14. Gilead Sciences, Inc.
    • 15.3.15. HEALIOS K.K.
    • 15.3.16. Integra LifeSciences Holdings Corporation
    • 15.3.17. JCR Pharmaceuticals Co., Ltd.
    • 15.3.18. Johnson & Johnson
    • 15.3.19. Merck KGaA
    • 15.3.20. Mesoblast Limited
    • 15.3.21. Novartis AG
    • 15.3.22. Orchard Therapeutics PLC
    • 15.3.23. Organogenesis Holdings Inc.
    • 15.3.24. Pfizer Inc.
    • 15.3.25. Pluri Biotech Ltd.
    • 15.3.26. Poseida Therapeutics, Inc.
    • 15.3.27. REPROCELL Inc.
    • 15.3.28. SanBio Company Limited
    • 15.3.29. Stryker Corporation
    • 15.3.30. Sumitomo Pharma Co., Ltd.
    • 15.3.31. Sysmex Corporation
    • 15.3.32. Takeda Pharmaceutical Company Limited
    • 15.3.33. Tenaya Therapeutics, Inc.
    • 15.3.34. Vericel Corporation
    • 15.3.35. Voyager Therapeutics Inc.
    • 15.3.36. Zimmer Biomet Holdings, Inc.

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. REGENERATIVE MEDICINE MARKET: RESEARCHAI
  • FIGURE 24. REGENERATIVE MEDICINE MARKET: RESEARCHSTATISTICS
  • FIGURE 25. REGENERATIVE MEDICINE MARKET: RESEARCHCONTACTS
  • FIGURE 26. REGENERATIVE MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL KILLER (NK) CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL KILLER (NK) CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY T CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY T CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-IMMUNE CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-IMMUNE CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STEM CELL-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STEM CELL-BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY EXTRACELLULAR & ACELLULAR THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY EXTRACELLULAR & ACELLULAR THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE EDITING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE EDITING TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RNA & DNA-BASED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RNA & DNA-BASED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL BIOMATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL BIOMATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC BIOMATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC BIOMATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SCAFFOLDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY XENOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY XENOGENEIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ANGIOGENESIS & VASCULAR REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ANGIOGENESIS & VASCULAR REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MYOCARDIAL INFARCTION TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MYOCARDIAL INFARCTION TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AESTHETIC PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AESTHETIC PROCEDURES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BURN TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BURN TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CHRONIC WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CHRONIC WOUND HEALING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BETA CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BETA CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ISLET CELL REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ISLET CELL REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALZHEIMER'S TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALZHEIMER'S TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MULTIPLE SCLEROSIS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MULTIPLE SCLEROSIS THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PARKINSON'S THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PARKINSON'S THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SPINAL CORD INJURY REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SPINAL CORD INJURY REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STROKE RECOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STROKE RECOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TUMOR ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TUMOR ABLATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CORNEAL REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CORNEAL REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RETINAL REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RETINAL REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BONE REGENERATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TENDON REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TENDON REPAIR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 185. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 193. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 195. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 243. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 245. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 247. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 248. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 249. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 250. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 251. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 253. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 255. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 257. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 261. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 265. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 269. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 275. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 277. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 279. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 282. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 283. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 284. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 285. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 286. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2025-2030 (USD MILLION)
  • TABLE 287. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
  • TABLE 289. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025-2030 (USD MILLION)
  • TABLE 291. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 292. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 293. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 295. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2025-2030 (USD MILLION)
  • TABLE 297. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 299. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2025-2030 (USD MILLION)
  • TABLE 303. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2025-2030 (USD MILLION)
  • TABLE 305. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
  • TABLE 311. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 313. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 314. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2025-2030 (USD MILLION)
  • TABLE 315. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 317. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2025-2030 (USD MILLION)
  • TABLE 319. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2025-2030 (USD MILLION)
  • TABLE 321. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIA